中國抗癌藥劑市場：2008年

中國抗癌藥劑市場：2008年 是由出版商Draco Healthcare Consulting, LLC在2008年12月所出版的。 這份英文市場調查報告書包含172 PAGES 價格從美金8000起跳。

簡介

目錄

Abstract

According to the statistics released by the Chinese Ministry of Health (MOH), there are 2.127 million Chinese patients with newly diagnosed tumors (both benign and malignant) each year; among which 1.06 million are newly diagnosed cancer patients. Cancer has become the leading cause for mortality in both urban and rural China. The cancer mortality rate of urban Chinese residents was 140.47/100,000 (21.82% of all urban deaths); the cancer mortality rate of rural Chinese residents was 111.57/100,000 (16.50% of all rural deaths), according to the national statistics data.

In the Chinese hospital drug market, sales of cancer drugs have rose steadily in recent years. During 2003-2005, the annual compound growth rate of cancer drug sales was about 24.53%. In 2006, due to the national campaign on anti-commercial bribery as well as other related government policies, the market growth of cancer drugs slowed down to 11.10%. However, the growth of cancer drug market regained its momentum and reached a 22.24% annual growth rate in 2007. 2007' s total market size for cancer drugs in China was RMB 25.45 billion RMB (USD 3.63 billion at a 7:1 USD:RMB exchange rate).

This report has systemically analyzed the Chinese cancer drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

Market shares from all major players including multinational and Chinese pharmaceutical companies and their major cancer s products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major cancer drugs will present you a clear picture of the competition landscape of Chinese cancer s drug market and the market potential for your company' s product(s) that already marketed in China or if you are planning to bring your drugs to the China market. This China Cancer Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.

Table of Contents

Methodology for the China Drug Market Reports 2008

The China Anti-Cancer Drug Market Report 2008

Prologue

• Section 1: Basic Concepts of Tumor
• Section 2: Basic Classifications of Tumor
• Section 2: Basic Types of Tumor
• Section 4: Summary of Treatment Options for Common Cancers in China
• Section 5: Summary of Cancer Incidences
  • Cancer Incidence in the World............
  • Cancer Incidence and Mortality in China

Chapter I: Summary of Anti-Cancer Drugs in China

• Section 1: Classifications of Anti-cancer Drugs
  • Alkaloid and other natural products
  • Cytotoxic antibiotics and related products
  • Anti-metabolites
  • Alkylating agents
  • Other types
• Section 2: History of Anti-cancer Drug Development in China
  • Generics vs. Innovative Anti-cancer Drugs in China ............
  • Anti-cancer Drug Production Capacity (1996-2006)

Chapter II: Summary of Global Markets of Anti-Cancer Drugs

• Section 1: New Anti-cancer Drugs Approved in 2007
  • New Molecular Entity (NME)
  • New Biologics
• Section 2: Summary of Global Anti-cancer Drug Market in 2007
  • The Top 10 Best Selling Therapeutic Categories ............
  • Anti-cancer Drugs Among the Top 50 Best Selling Drugs

Chapter III: Market Analysis of China' s Anti-Cancer Drugs

• Section 1: Hospital Market Sizes of Anti-cancer Drugs in China (2003-2007)
• Section 2: Analysis of Chinese Hospital Market Shares of Anti-cancer Drugs by Categories (2004-2007)
• Section 3: Hospital Market Shares of the Top 20 Anti-cancer Drugs in China (2006-2007)
• Section 4: Hospital Market Shares of Major Anti-cancer Drug Manufacturers (2006-2007)
• Section 5: Market Share Analysis of Key Anti-cancer Drugs by Categories in 2007
• Immune-stimulants
  • Manufacturers, Market Sizes and Shares for Recombinant G-CSF
  • Manufacturers, Market Sizes and Shares for Lentinan
  • Manufacturers, Market Sizes and Shares for Human Interleukin-2
• Natural Pruducts
  • Manufacturers, Market Sizes and Shares for Paclitaxel
  • Manufacturers, Market Sizes and Shares for Docetaxel
  • Manufacturers, Market Sizes and Shares for Vinorebine
• Anti-metabolites
  • Manufacturers, Market Sizes and Shares for Capecitabine
  • Manufacturers, Market Sizes and Shares for Gemcitabine
  • Manufacturers, Market Sizes and Shares for Pemetrexed
  • Cytotoxic antibiotics and Related drugs
  • Manufacturers, Market Sizes and Shares for Epirubicin
  • Manufacturers, Market Sizes and Shares for Pirarubicin
• Aromatase Inhibitors (AI) and Related Products
  • Manufacturers, Market Sizes and Shares for Letrozol
  • Manufacturers, Market Sizes and Shares for Anastrozole
  • Manufacturers, Market Sizes and Shares for Flutamide
• Hormone and Related Products
  • Manufacturers, Market Sizes and Shares for Triptorelin
  • Manufacturers, Market Sizes and Shares for Goserelin
  • Manufacturers, Market Sizes and Shares for Leuprorelin
• Alkylating Agents
  • Manufacturers, Market Sizes and Shares for Isophosphamide
  • Manufacturers, Market Sizes and Shares for Busulfan
• All Other Anti-cancer Drugs
  • Manufacturers, Market Sizes and Shares for Oxaliplatin
  • Manufacturers, Market Sizes and Shares for Rituximab
  • Manufacturers, Market Sizes and Shares for Gefitinib

Chapter IV: List of Brand Names, Generic Names of Anti-cancer Drugs and Their Corresponding Manufacturers in China

Chapter V: Packages and Prices of Anti-cancer Drugs in China and Anti-cancer Drugs on the National Healthcare Insurance Coverage List

• Section 1: Package, Unit, Quality Certification (GMP generics or Patent-protected), Retail Price of Anti-cancer Drugs and Their Manufacturers
• Section 2: Anti-cancer Drugs On the National Healthcare Insurance and Work-related Insurance Lists
• Types of Insurance, Formula and Reimbursement Restriction

Chapter VI: Regulatory and Government Policies for Anti-Cancer Drugs in China

Chapter VII: Current Anti-Cancer Drug Development in China

• Section 1: Pipeline Assessment of Western Anti-cancer Drugs Under Clinical Studies
• Section 2: Pipeline Assessment of Chinese Natural Anti-cancer Products under Clinical Studies

Exhibits

Tables

• Table A. Hospital Coverage for Drug Prescrption and Purchasing Data Monitor and Tracking in China
• Table 1: Comparison of Benign Tumors with Malignant Tumors
• Table 2: Cancer Disease Rates in China in Recent Years
• Table 3: The Bi-weekly Tumor Disease Morbidity Rates for Different Age Group
• Table 4: Tumor Mortalities in China (MOH)
• Table 5: Newly Approved Anti-cancer NMEs Worldwide in 2007
• Table 6: Newly Approved Anti-cancer Biologics Worldwide in 2007
• Table 7: Top 10 Best Selling Therapeutic Categories in 2007
• Table 8: Anti-cancer Drugs Among the Top 50 Best Selling Drugs in 2006
• Table 9: Chinese Hospital Market Shares of Cancer Drug Categories (2004 - 2007)
• Table 9-1: Chinese Hospital Sales of Cancer Drug Categories (2004 - 2007)
• Table 10: Chinese Hospital Market Shares of the Top 20 Cancer Drugs (2006 -2007)
• Table 11: Chinese Hospital Shares of the Top Pharmaceutical Companies in the Chinese Anti-cancer Drug Market (2006- 2007)
• Table 12: Ranking of Top 5 Anti-cancer Drugs in Each Category by Hospital Utilization (Revenue) 2007
• Table 13: Manufacturers, Market Sizes and Shares for Recombinant G-CSF 2007
• Table 14: Manufacturers, Market Sizes and Shares for Lentinan 2007
• Table 15: Manufacturers, Market Sizes and Shares for rh-Interleukin-2 2007
• Table 16: Manufacturers, Market Sizes and Shares for Paclitaxel 2007
• Table 17: Manufacturers, Market Sizes and Shares for Docetaxel 2007
• Table 18: Manufacturers, Market Sizes and Shares for Vinorebine 2007
• Table 19: Manufacturers, Market Sizes and Shares for Gemcitabine 2007
• Table 20: Manufacturers, Market Sizes and Shares for Pemetrexed 2007
• Table 21: Manufacturers, Market Sizes and Shares for Epirubicin 2007
• Table 22: Manufacturers, Market Sizes and Shares for Pirarubicin 2007
• Table 23: Manufacturers, Market Sizes and Shares for Letrozol 2007
• Table 24: Manufacturers, Market Sizes and Shares for Anastrozole 2007
• Table 25: Manufacturers, Market Sizes and Shares for Flutamide 2007
• Table 26: Manufacturers, Market Sizes and Shares for Triptorelin 2007
• Table 27: Manufacturers, Market Sizes and Shares for Ifosfamide 2007
• Table 28: Manufacturers, Market Sizes and Shares for Busulfan 2007
• Table 29: Manufacturers, Market Sizes and Shares for Oxaliplatin 2007
• Table 30: Brand and Generic Names of Anti-cancer Drugs and Manufacturers in China
• Table 31: Packages and Retail Prices of Anti-cancer Drugs in China
• Table 32: Anti-cancer Drugs Listed on the National Healthcare Insurance Coverage List and on the Worker' s Injury Insurance List

Figures

• Figure 1: Age Distribution of Sampled Chinese Population
• Figure 2: Annual Production of Anti-cancer Drugs in China (1993-2007)
• Figure 3: Total Sales and Annual Growth Rates of Anti-cancer Drug Market in China (2003-2007)

THE TOP 20 PHARMACEUTICAL COMPANIES (WITH AT LEAST >1.3% OF THE CHINA ANTI-CANCER DRUG MARKET) IN 2007

• Jiangsu Hansen Pharmaceutical Co., Ltd.(Hansen Pharma)
• Jiangsu Hengrui Medicine Co., Ltd.
• Novartis
• Pfizer
• Roche
• sanofi-aventis
• Sichuan Diao Jiuhong Group Pharmaceutical Co.
• AstraZeneca
• Bristol-Myers Squibb
• Eli Lilly & Co.
• Guizhou Baiqiang Pharmaceutical Co., Ltd.
• Hainan Zhonghe Pharmaceutical Co., Ltd.
• Jinling Pharmaceutical Co. Ltd.
• Livzon Pharmaceutical Group Inc.
• Nanjing Kanghai Pharmaceutical Co., Ltd.
• Nanjing Sike Pharmaceutical Co., Ltd.
• Qilu Pharmaceutical Co., Ltd.
• SciClone Pharmaceuticals Italy S.R.L.
• Shenzhen Wanle Pharmaceutical Co,.Ltd.
• Zhejiang Hisun Pharmaceutical Co,.Ltd.

相關商品

癌症相關市場調查報告書

膀胱癌相關的各種合作趨勢:2007-2012年
Bladder Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

腦瘤相關的各種合作趨勢:2007-2012年
Brain Cancer Partnering 2007-2012
價格 : US $ 995
出版日期 : 2012年05月

乳癌相關的各種合作趨勢:2007-2012年
Breast Cancer Partnering 2007-2012
價格 : US $ 1695
出版日期 : 2012年05月

Draco Healthcare Consulting, LLC發行的製藥相關市場調查報告書

中國糖尿病治療藥市場：2008年

China: Anti-Diabetic Drug Market Report 2008

價格 : US $ 8000

出版日期 : 2009年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!